An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

@article{Dharmapuri2009AnOT,
  title={An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models},
  author={S. Dharmapuri and L. Aurisicchio and P. Neuner and M. Verdirame and G. Ciliberto and N. L. Monica},
  journal={Cancer Gene Therapy},
  year={2009},
  volume={16},
  pages={462-472}
}
In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species. To further enhance the efficacy of DNA-EP, we have evaluated the toll-like receptor7 (TLR7) agonist—2, 9, substituted 8-hydroxyadenosine derivative or SM360320—as an adjuvant to vaccines against HER2/neu and CEA in BALB-neuT and CEA transgenic mice (CEA.Tg… Expand
Emerging Cancer Vaccines: The Promise of Genetic Vectors
Cripto-1: potential target for cancer immunotherapy?!
...
1
2
3
...

References

SHOWING 1-10 OF 53 REFERENCES
Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector
Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo
  • Georg Widera, Melissa Austin, +8 authors Jeffrey B. Ulmer
  • Biology, Medicine
  • The Journal of Immunology
  • 2000
Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant1
...
1
2
3
4
5
...